Cargando…
639. Are SARS-CoV-2 antigenemia measurements still relevant? Comparison of Omicron era to early pandemic plasma nucleocapsid levels
BACKGROUND: Viral nucleocapsid in the blood (antigenemia) is a sensitive marker of acute COVID-19 and is supported in numerous published studies to have diagnostic and prognostic value. Review of the literature shows that nearly all antigenemia studies published as of February 25, 2023 precede the e...
Autores principales: | Damhorst, Gregory L, Verkerke, Hans, Martin, Sydney E, Wilber, Eli, Lam, Wilbur A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677356/ http://dx.doi.org/10.1093/ofid/ofad500.703 |
Ejemplares similares
-
Nucleocapsid Antigenemia in Patients Receiving Anti-CD20 Therapy With Protracted COVID-19
por: Wilber, Eli, et al.
Publicado: (2022) -
Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection( )
por: Verkerke, Hans P, et al.
Publicado: (2022) -
Investigation of Blood Plasma Viral Nucleocapsid Antigen as a Marker of Active Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Infection
por: Damhorst, Gregory L, et al.
Publicado: (2023) -
Opportunistic Cryptococcal Antigenemia in the HAART Era at HIV Epidemic Settings of Northwest Ethiopia
por: Negash, Markos, et al.
Publicado: (2020) -
Omicron still on the rise
por: Wilson, Clare
Publicado: (2022)